DESTINY-Breast03 Phase 3 Study Results

DESTINY-Breast03 Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2-Positive Unresectable and/or Metastatic Breast Cancer: Safety Follow-up of the Randomized, Phase 3 Study DESTINY-Breast03 Erika Hamilton, MD, a Vanessa Petry, Winnie Yeo, Sung-Bae Kim, Giampaolo Bianchini, Toshinari Yamashita, Kan Yonemori, Kenichi Inoue, Giuseppe Curigliano, Sara A. Hurvitz, Javier Cortés, Hiroji Iwata, Jillian Cathcart, Yali Liu, Caleb Lee, Emarjola Bako, Rachel Kim, Seock-Ah Im On behalf of the DESTINY-Breast03 investigators aSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA Daiichi-Sankyo ASCO 2022 #1000 Oral On behalf of the investigators 23

View entire presentation